More MS news articles for Oct 2001

MSActiveSource, a New Online Resource for People With Multiple Sclerosis, Posts Revised FAA Guidelines for Air Travelers with Injectable MS Therapies

Fri, Oct 26 12:59 PM EDT

CAMBRIDGE, Mass., Oct. 26 /PRNewswire/ -- Biogen, Inc. (NASDAQ:BGEN) today announced that new Federal Aviation Administration (FAA) guidelines for people traveling with multiple sclerosis (MS) medications and syringes are now available on MSActiveSource, an online resource for the MS community.

Intensified airline security in the aftermath of the tragic events of September 11 has caused changes in policies regarding carrying medication and injection systems onboard airline carriers. Biogen officials have spoken with representatives from the FAA and the most up-to-date information about security screening procedures and traveling with MS medications in carry-on luggage has now been posted on MSActiveSource. People with MS are advised to check the site frequently, as policies may change. They are also advised to contact their specific airline carriers directly.

"Importantly, people with MS should know that they can still travel with their medication and injection systems in their carry-on luggage as advised, provided they follow the new FAA guidelines," said James C. Mullen, Biogen's President and Chief Executive Officer. "We are pleased to offer as a resource for all people with MS planning to board an airplane in the near future."

This information is particularly timely as many people with MS prepare to travel to New Orleans, LA, for the National Multiple Sclerosis Society's (NMSS) Annual Leadership Conference taking place October 30 -- November 2, 2001. According to the NMSS, over 800 people from across the country are expected to attend the meeting. For more information, call 1-800-FIGHTMS.

MSActiveSource -- An Online Multiple Sclerosis Resource and Community

MSActiveSource is a comprehensive Internet site for people living with multiple sclerosis, their friends and families, and healthcare professionals. The site, launched earlier this year, offers personalized support and in-depth information to help better understand and manage the physical and emotional challenges of MS. Site members are provided a broad selection of resources, including disease information, comprehensive news, community, and the latest research studies that are improving doctors' understanding of MS.

MSActiveSource is composed of several one-of-a-kind elements, including the MS Learning System(TM), an interactive multimedia learning tool that takes people with MS and their families through a series of educational modules to help them better understand and cope with the disease. The site also hosts an "Ask the Expert" column featuring leading neurologists specializing in MS treatment and articles designed to help people with MS better understand and manage their disease. Another interactive component of the site is the "MS Experience Exchange" which provides a forum for sharing thoughts and ideas between others affected by the disease. The MS News section of the site is updated daily with articles from a syndicated network of nearly 3,000 publications.

For people without Internet access -- or those who prefer to speak to someone by telephone -- Biogen continues to provide support through the ActiveSource(SM) support line Monday through Friday, 8:30 a.m. -- 8 p.m. EST at 800-456-2255.

Biogen, Inc., winner of the U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company's revenues are generated from international sales of AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen's research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen's Homepage on the World Wide Web at .
©2001 At Home Corporation